OUR PRODUCTS

Latest products

MORE PRODUCTS
[按钮标题=“更多产品”链接=”http://121.41.79.180/index.php/our-products/“target="”align="”icon="”icon_position="”color="”font_color="”size=“2”full_width="”class="”download="”rel="”onclick=""]

OUR SERVICES


Specialized extracellular vesicles
research services tailored to the customs


ABOUT US关于我们关于我们


[分隔器高度=“10”]
[分隔器高度=“10”][分隔器高度=“10”]

Experience & trust built for 6 years5年的经验和信任
5年来建立的经验信任


[分隔器高度=“15”]
[分隔器高度=“15”][分隔器高度=“15”]

Specialized in extracellular vesicle clinical medical research.
专业从事细胞外囊泡的临床医学研究。
专业从事细胞外囊泡的临床医学研究。

SR Bio-Tech was founded by top-notch doctoral graduates from domestic and international universities in March 2018, with a registered capital of 10.1 million RMB. The company focuses on exosome isolation and capture, exosomal nucleic acids, and protein capture detection diagnostic technologies. Its primary goal is to achieve the diagnosis and treatment of common clinical tumors. Shengran Biotechnology integrates the research and development, production, and sales of exosome tumor panel diagnostic reagents, as well as the development of exosome capture and detection instruments. The company is committed to innovative endeavors in the field, including the development of tumor treatment technologies based on exosomes.
盛然生物科技于2018年3月由国内外高校优秀博士毕业生创办,注册资本1010万人民币。该公司专注于外泌体分离和捕获,外泌体核酸和蛋白质捕获检测诊断技术。其主要目标是实现临床常见肿瘤的诊断和治疗。盛然生物集外泌体肿瘤面板诊断试剂的研发、生产和销售,以及外泌体捕获和检测仪器的开发为一体。该公司致力于该领域的创新努力,包括开发基于外泌体的肿瘤治疗技术。
SR-TECH于2018年3月由来自国内外大学的顶尖博士毕业生创立,注册资本1010万人民币。该公司专注于外泌体分离和捕获,外泌体核酸和蛋白质捕获检测诊断技术。其主要目标是实现临床常见肿瘤的诊断和治疗。盛然生物集外泌体肿瘤面板诊断试剂的研发、生产和销售,以及外泌体捕获和检测仪器的开发为一体。该公司致力于该领域的创新努力,包括开发基于外泌体的肿瘤治疗技术。
盛然生物科技于2018年3月由国内外高校优秀博士毕业生创办,注册资本1010万人民币。该公司专注于外泌体分离和捕获,外泌体核酸和蛋白质捕获检测诊断技术。其主要目标是实现临床常见肿瘤的诊断和治疗。盛然生物集外泌体肿瘤面板诊断试剂的研发、生产和销售,以及外泌体捕获和检测仪器的开发为一体。该公司致力于该领域的创新努力,包括开发基于外泌体的肿瘤治疗技术。


ABOUT US

20

Publication

12

Patents

5
0

Awards

500

Diagnose  Patients